Floatz logo

8 assets in Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance

Therapeutic assets addressing Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (66)
Brentuximab Vedotin
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (66)
Dacarbazine
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (66)
Vinblastine
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (66)
Nivolumab
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3BB (64)
Nivestim
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3B (60)
Pegfilgrastim
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
National Cancer Institute (NCI)P3B (60)
Bleomycin
Hodgkin'S Lymphoma, Lymphocytic-Histiocytic Predominance
City of Hope Medical CenterP2CCC (53)